Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunotherapy development platform, has entered into securities purchase and warrant inducement agreements with an existing institutional investor. The transaction is expected to generate approximately $4 million in aggregate gross proceeds, a move that underscores the company’s strategy to bolster both its service business and its therapeutic development efforts.
The private placement includes 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, together with warrants to purchase up to 3,687,501 additional ADSs, at a combined purchase price of $1.20 per ADS and accompanying warrants. Additionally, under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and receive new warrants to purchase up to 1,318,791 ADSs. The transactions are expected to close on or about Oct. 15, 2026, subject to customary conditions.
The net proceeds, combined with existing cash resources, are intended to expand Scinai’s CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. This allocation reflects the company’s dual focus: generating revenue through manufacturing services while developing innovative immunology therapies. The newly issued Series A-1 warrants will be immediately exercisable at $1.20 per ADS and have five-year terms. A.G.P./Alliance Global Partners is serving as sole placement agent for the transactions.
The importance of this announcement lies in its potential to accelerate Scinai’s growth on multiple fronts. By injecting capital into the CDMO platform, the company aims to enhance its ability to serve biotechnology and pharmaceutical clients through its facilities in Jerusalem and Yavne, Israel. Simultaneously, continued investment in the immunotherapy pipeline—which includes candidates licensed from the Max Planck Society and PinCell S.r.l.—positions Scinai to make progress on novel treatments. For investors, the transaction demonstrates ongoing support from an institutional backer and provides a clearer picture of how Scinai plans to fund its operations and strategic priorities.
As a Nasdaq-listed company, Scinai operates in a competitive biopharmaceutical landscape where access to capital is critical for sustaining research and development while scaling service offerings. This financing arrangement, which includes both new capital and the inducement of existing warrants, could strengthen the company’s balance sheet and provide the flexibility needed to execute its business plan. Further details are available in the full press release at https://ibn.fm/eUtYO, and ongoing updates can be found in the company’s newsroom at https://ibn.fm/SCNI.
The announcement was disseminated through MissionIR, a communications platform that is part of the Dynamic Brand Portfolio at IBN. MissionIR provides services including wire distribution via InvestorWire and editorial syndication to 5,000+ outlets, helping companies like Scinai reach a broad investor audience.
